Abstract #1161775: Semaglutide-induced leukocytoclastic vasculitis

Semaglutide is a GLP-1 receptor agonist approved for treatment of type 2 diabetes mellitus. Common side effects include mild and transient gastrointestinal disturbance. It increases the risk of cholelithiasis. No major safety concerns have arisen to date, although definitive conclusions regarding risk of pancreatic and medullary thyroid cancer cannot be drawn at this point. We describe a patient who developed leukocytoclastic vasculitis with oral semaglutide.